OSTX Stock Forecast: OS Therapies, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for OS Therapies, Inc. is $7. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 23 of 100 as at 21 Nov 2026 — in the weakest quartile.
One number for the whole business
Consensus tells you what everyone already believes. The model scores OS Therapies, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (85): Reported profit is backed by cash, and the company is not expanding recklessly.
Issuance (6): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
OSTX stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on OSTX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 9 July 2026 | Roth Capital | Initiates | Buy | — |
| 19 May 2026 | Lake Street | Maintains | Buy | — |
| 30 Apr 2026 | D. Boral Capital | Maintains | Buy | — |
| 8 Apr 2026 | D. Boral Capital | Maintains | Buy | — |
| 27 Mar 2026 | D. Boral Capital | Maintains | Buy | — |
| 9 Mar 2026 | D. Boral Capital | Maintains | Buy | — |
| 5 Feb 2026 | D. Boral Capital | Maintains | Buy | — |
| 5 Jan 2026 | D. Boral Capital | Maintains | Buy | — |
| 15 Dec 2025 | D. Boral Capital | Maintains | Buy | — |
| 9 Dec 2025 | D. Boral Capital | Maintains | Buy | — |
| 5 Dec 2025 | D. Boral Capital | Maintains | Buy | — |
| 21 Nov 2025 | D. Boral Capital | Maintains | Buy | — |
| 18 Nov 2025 | Lake Street | Maintains | Buy | — |
| 17 Nov 2025 | D. Boral Capital | Maintains | Buy | — |
| 10 Oct 2025 | D. Boral Capital | Maintains | Buy | — |
| 30 Sept 2025 | D. Boral Capital | Maintains | Buy | — |
| 12 Sept 2025 | D. Boral Capital | Maintains | Buy | — |
| 2 Sept 2025 | D. Boral Capital | Maintains | Buy | — |
| 27 Aug 2025 | D. Boral Capital | Maintains | Buy | — |
| 20 Aug 2025 | D. Boral Capital | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for OSTX.
This page is one stock. Monday covers all of them.
OSTX appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
OSTX vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, OS Therapies, Inc. returned −50.4% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
OSTX analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- —
- Price / book
- —
- EV / EBITDA
- —
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- —
- Return on assets
- −291.4%
- Dividend yield
- —
Higher than 1% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
OS Therapies, Inc. has a market value of $42.0M and an enterprise value of $44.6M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$39.4M.
Free cash flow in the twelve months to 30 June 2026: −$18.5M.
forward P/E: 2.3× — the forward figure prices analyst consensus estimates, not reported earnings.
OS Therapies, Inc. employs 4 people.
Data provided by Twelve Data
OSTX and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at OSTX’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own OS Therapies, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about OSTX
What is the OSTX stock price forecast for 2026-2027?
The median 12-month analyst price target for OS Therapies, Inc. is $7, with estimates ranging from $6 to $13. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is OSTX stock a buy right now?
Of the 4 analysts covering OS Therapies, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks OS Therapies, Inc. 23 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank OSTX?
As at 21 Nov 2026, OS Therapies, Inc. ranks 23 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (85 of 100).
Will OSTX stock go up?
No one can know that. What the data says: the median 12-month target from 4 analysts is $7, and Ticker Nerd's factor model ranks OS Therapies, Inc. 23 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the OSTX stock forecast for 2030?
No analyst covering OS Therapies, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for OSTX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $6 to $13 over the next 12 months.
How has OSTX stock performed over the past year?
OS Therapies, Inc. returned -50.4% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does OS Therapies, Inc. do?
OS Therapies Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing treatments for osteosarcoma and other solid tumors. The company’s current work centers on oncology programs that aim to harness the immune system against cancers expressing HER2, including its lead immunotherapy candidate OST-HER2.
About OS Therapies, Inc.
OS Therapies Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing treatments for osteosarcoma and other solid tumors. The company’s current work centers on oncology programs that aim to harness the immune system against cancers expressing HER2, including its lead immunotherapy candidate OST-HER2. OS Therapies also advances an antibody-drug conjugate platform designed to support targeted cancer therapy development. Its product pipeline is directed toward high-unmet-need cancers, particularly rare bone cancers and other HER2-related solid tumors. Based in Grasonville, Maryland, OS Therapies Inc. operates within the biotechnology sector as a development-stage company focused on investigational cancer treatments and platform technologies for future clinical use.
CEO Mr. Paul A. Romness M.P.H. · 4 employees · United States · https://ostherapies.com